AI summary · may contain errors
A gene-edited porcine kidney xenograft (EGEN-2784) in a human recipient sustained dialysis independence for 271 days before graft failure and nephrectomy.
- 1 cited this week
Elsevier BV · General Science & Medicine · ISSN 0140-6736
Rebuilt
AI summary · may contain errors
A gene-edited porcine kidney xenograft (EGEN-2784) in a human recipient sustained dialysis independence for 271 days before graft failure and nephrectomy.
AI summary · may contain errors
In AMI complicated by cardiogenic shock, cangrelor produced platelet reactivity index <50% in 100% versus 22% with crushed ticagrelor at end of primary PCI.
AI summary · may contain errors
Robotic-arm-assisted total knee replacement using the Mako system did not improve 12-month patient outcomes versus conventional instruments, with an adjusted Forgotten Joint Score difference of -1·5.
Newest first · last 60 days
AI summary · may contain errors
TriPRIL, an APRIL-based dual-target CAR T-cell therapy for relapsed or refractory multiple myeloma, showed no dose-limiting toxicities at 1×10^8 or 3×10^8 cells in 15 infused patients.
AI summary · may contain errors
Empirical tuberculosis treatment added to standard care did not reduce all-cause mortality versus a clinically and microbiologically guided strategy in 558 infants with severe HIV-associated pneumonia.
AI summary · may contain errors
Empirical valganciclovir in infants aged 28–365 days hospitalized with severe HIV-associated pneumonia is linked to lower day-15 mortality (rate ratio 0·81, 95% CI 0·61–1·08).
AI summary · may contain errors
First-line pembrolizumab improved progression-free survival versus carboplatin plus paclitaxel in mismatch repair-deficient advanced or recurrent endometrial cancer, with median 38·2 vs 8·4 months.
AI summary · may contain errors
Ambient scribes as AI voice-to-text tools are widely promoted for saving clinician time, but their risks are often unacknowledged and can undermine patient-centred care.
AI summary · may contain errors
In Japan’s PRABITAS phase 3 trial for refractory metastatic colorectal cancer, a 14-day FTD-TPI plus bevacizumab schedule was non-inferior for overall survival versus 28 days (median 11·3 vs 10·3 months; stratified HR 0·93).
Journals this month
Topics moving, week to 18 Nov 2026
By field